Mission & Vision
Extracting the Science & Formulating Superior Therapeutics
At Pivotal Therapeutics, our first novel product, VASCAZENTM, represents the first medical food in the US market specifically for the dietary management of cardiovascular disease in patients manifesting an Omega-3 deficiency.
George Jackowski, Ph.D
Chairman, Chief Scientific Officer
Dr. Jackowski has been instrumental in the founding of nine biotechnology companies in his career, four of which are public. Furthermore, he has contributed to the creation of 12 additional biotechnology companies. He has grown companies to market caps of over $350 million, raised from public capital markets over $125 million and completed deals with Big Pharma of over $100 million USD in transactions. His most recent experience is as Chairman, CEO and CSO of SynX Pharma Inc., which he founded in 1997 and was acquired by Nanogen Inc., a San Diego based company. Dr. Jackowski holds Directorships in numerous biotech companies. Dr. Jackowski holds academic positions at the University of Toronto in the Department of Laboratory Medicine and Pathobiology and the Department of Surgery. He also served in the past as the Chairman of Bio Canada Connect, was a Board Member of the Ontario BIOCouncil and on the Board of Directors for the Canadian Stroke Network. His scientific resume includes authoring 44 publications and 61 abstracts, holding over 136 patents filed and issued, and receiving the 1996 MEDEC Award for Medical Achievement for his invention of the Cardiac STATUS™ CK-MB/Myoglobin Card Test, which aids in the early diagnosis of myocardial infarction and is commercialized worldwide in hospital emergency rooms. Dr. Jackowski has also served on many federal and provincial governmental biotechnology committees. Dr. Jackowski has been intimately involved in the enforcement of patent claims, patent litigation and patent interference proceedings. Dr. Jackowski, a respected cardiovascular biochemist, received his training at the Cardiovascular Research Institute at the University of San Francisco, California. Dr. Jackowski has over 25 years experience and extensive networks in the cardiovascular and CNS disease markets, particularly pertaining to the commercialization of diagnostic products.
Eugene Bortoluzzi, B.Com., MBA
Chief Executive Officer, Chief Financial Officer
Mr. Bortoluzzi is a Senior Finance Executive with significant experience in public and private companies ranging from small business environments to TSE and NASDAQ listed international organizations. He is an executive leader with a breadth of responsibility encompassing human resources, administration, finance, treasury, investor relations, operations and new business development. He has over 12 years experience in managing biotechnology companies. Mr Bortoluzzi’s areas of expertise include: Strategic Planning, Financial Management, Turnarounds, Mergers and Acquisitions, Investments and Analysis, Financial Modeling, Track Record of Raising Capital and Structuring Major Business Deals, Operational Management, Business Development, GPO/Purchasing Contract Negotiations, Track Record of International Sourcing/Trade Relations, US and Canada Regulatory Reporting ensuring complete and ethical disclosure.
Rachelle MacSweeney, B.Sc., MBA
Mrs. MacSweeney has spent a number of years acting as a marketing and business development consultant. Mrs. MacSweeney has worked for a number of companies in a variety of industry sectors, including, but not limited to, the biotechnology industry, the healthcare and homecare product industry, the aerospace and defense industries, and post-secondary education. Mrs. MacSweeney brings to Pivotal a well-rounded and polished understanding of Business Development, as well as a bright and creative talent for marketing. Mrs. MacSweeney holds an Honours degree in Biomedical Science from the University of Guelph and a Masters Business Administration from Dalhousie University, with specific interests and areas of expertise in marketing, new venture creation, product management/development, and entrepreneurial studies.
Jason Yantha, Ph.D
Director Scientific Operations & Medical Communications
Dr. Yantha brings to Pivotal a broad understanding & extensive research experience in immunity and related disease as well as diagnostics, proteomics & discovery of blood biomarkers. Prior to joining Pivotal, he gained experience at SynX Pharma as a research scientist for the proteomics & discovery division of the company. In this role, he directed efforts that contributed to over 30 granted US patents. Dr. Yantha received his doctorate from the University of Toronto with a research focus on immunology and autoimmune diseases. For his doctorate, Dr. Yantha identified a neuronal link in the development of type I diabetes and developed a neurosurgical procedure that protects against the onset of, and reverses diabetes in animal models.